GlaxoSmithKline PLC (NYSE:GSK) Downgraded by Investec to “Hold”

GlaxoSmithKline PLC (NYSE:GSK) was downgraded by stock analysts at Investec from a “buy” rating to a “hold” rating in a research report issued on Monday, November 6th, Marketbeat.com reports.

Several other analysts have also recently weighed in on the stock. TheStreet raised shares of GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Bank of America Corporation cut shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, October 24th. Finally, Morgan Stanley cut shares of GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a report on Friday, September 8th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company. GlaxoSmithKline PLC currently has an average rating of “Hold” and an average price target of $44.33.

Shares of GlaxoSmithKline PLC (GSK) traded down $0.13 during mid-day trading on Monday, reaching $35.06. 2,585,265 shares of the company’s stock traded hands, compared to its average volume of 6,662,965. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline PLC has a one year low of $34.72 and a one year high of $44.53. The stock has a market capitalization of $86,224.50, a price-to-earnings ratio of 12.43, a PEG ratio of 1.94 and a beta of 1.00.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/glaxosmithkline-plc-gsk-rating-lowered-to-hold-at-investec-2/1762857.html.

In other news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. 1st Global Advisors Inc. increased its stake in shares of GlaxoSmithKline PLC by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock valued at $227,000 after acquiring an additional 19 shares during the last quarter. Carroll Financial Associates Inc. grew its holdings in shares of GlaxoSmithKline PLC by 0.4% during the 2nd quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock worth $374,000 after purchasing an additional 35 shares during the period. King Luther Capital Management Corp grew its holdings in shares of GlaxoSmithKline PLC by 1.0% during the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after purchasing an additional 55 shares during the period. First National Bank of Omaha grew its holdings in shares of GlaxoSmithKline PLC by 0.3% during the 2nd quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock worth $827,000 after purchasing an additional 57 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in shares of GlaxoSmithKline PLC by 1.9% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 64 shares during the period. 9.84% of the stock is owned by institutional investors.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.